Ruxolitinib as a primary treatment for multiple myeloma in a patient with primary myelofibrosis? A case report and the review of the literature

An 80-year-old female with a history of primary myelofibrosis was admitted to the hospital due to worsening symptoms of the primary disease. A secondary tumor — multiple myeloma (MM) — was revealed during the diagnostic process. Monotherapy with a JAK inhibitor (ruxolitinib) was administered, and the severity of both malignancies was alleviated. This article includes a short review of secondary malignancies correlated with PMF and the state of knowledge on using JAK inhibitors, mainly ruxolitinib, in treating MM.